AU2001249182A1 - Use of rapamycin and agents that inhibit b7 activity in immunomodulation - Google Patents

Use of rapamycin and agents that inhibit b7 activity in immunomodulation

Info

Publication number
AU2001249182A1
AU2001249182A1 AU2001249182A AU4918201A AU2001249182A1 AU 2001249182 A1 AU2001249182 A1 AU 2001249182A1 AU 2001249182 A AU2001249182 A AU 2001249182A AU 4918201 A AU4918201 A AU 4918201A AU 2001249182 A1 AU2001249182 A1 AU 2001249182A1
Authority
AU
Australia
Prior art keywords
immunomodulation
rapamycin
inhibit
agents
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249182A
Inventor
Mark J. Collins
Joseph Sypek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of AU2001249182A1 publication Critical patent/AU2001249182A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AU2001249182A 2000-03-14 2001-03-13 Use of rapamycin and agents that inhibit b7 activity in immunomodulation Abandoned AU2001249182A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18910600P 2000-03-14 2000-03-14
US60189106 2000-03-14
PCT/US2001/008016 WO2001068133A1 (en) 2000-03-14 2001-03-13 Use of rapamycin and agents that inhibit b7 activity in immunomodulation

Publications (1)

Publication Number Publication Date
AU2001249182A1 true AU2001249182A1 (en) 2001-09-24

Family

ID=22695958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249182A Abandoned AU2001249182A1 (en) 2000-03-14 2001-03-13 Use of rapamycin and agents that inhibit b7 activity in immunomodulation

Country Status (3)

Country Link
US (2) US20010055593A1 (en)
AU (1) AU2001249182A1 (en)
WO (1) WO2001068133A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
EP1599502A1 (en) * 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
CN103517716A (en) 2011-04-29 2014-01-15 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
BR112015027297B1 (en) 2013-05-03 2023-01-10 Selecta Biosciences, Inc USE OF SYNTHETIC NANOCARRIERS WHICH ARE ATTACHED TO IMMUNOSUPPRESSANTS AND A COMPOSITION COMPRISING SAID NANOCARRIERS
CA2957808A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
EP3592389A1 (en) 2017-03-11 2020-01-15 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5202332A (en) * 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
DK0633783T3 (en) * 1992-03-30 2000-09-25 American Home Prod Rapamycin preparation for intravenous injection
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5942607A (en) * 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AU5709798A (en) * 1997-01-10 1998-08-03 Biogen, Inc. Treatment of lupus nephritis with anti-cd40l compounds
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
SK156099A3 (en) * 1997-05-17 2000-06-12 Biogen Inc Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
EP0988321A2 (en) * 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
ATE430149T1 (en) * 1998-03-04 2009-05-15 Bristol Myers Squibb Co HETEROCYCLE SUBSTITUTED IMIDAZOPYRAZINE AS PROTEIN TYROSINE KINASE INHIBITORS
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
WO2000047625A2 (en) * 1999-02-12 2000-08-17 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
WO2001014556A1 (en) * 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor

Also Published As

Publication number Publication date
US20070092506A1 (en) 2007-04-26
US20010055593A1 (en) 2001-12-27
WO2001068133A1 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
AU2609901A (en) Antimicrobial compositions and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
IL148657A0 (en) Stent range transducers and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001253126A1 (en) (+) naloxone and epinephrine combination therapy
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001241729A1 (en) Protected forms of pharmacologically active agents and uses therefor
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU5437700A (en) Absorbent article that contains an active additive and use of a visual indicator in an absorbent article
AU2001233951A1 (en) Improvements in and relating to active noise reduction
AU2002366201A1 (en) Use of defined copolymers as adjuvants and agents in the agrotechnical domain
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU4848200A (en) Intravascular device and methods of manufacture and use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU8037900A (en) Modular processing devices and methods of use
AU2001249182A1 (en) Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU3732500A (en) Beclin and uses thereof
AU2001275036A1 (en) Protected forms of a combination of pharmacologically active agents and uses therefor
AU2001261375A1 (en) Human caspase-12 materials and methods
AU3501700A (en) Human endokine alpha and methods of use
AU6519198A (en) Melaninization inhibitor, skin-care preparation, and bath agent
AU2001259441A1 (en) Cellular regulators of infectious agents and methods of use
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001268236A1 (en) Use of aicar and related compounds
AU6102899A (en) Production and use of antimicrobial agents